The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis
- 701 Downloads
This multicenter and randomized clinical trial showed that daily oral herbal formula Xian Ling Gu Bao (XLGB) was safe in postmenopausal women over a 1-year treatment. Those patients (n ∼ 50) treated with XLGB at the conventional dose demonstrated a statistically significant increase in dual-energy X-ray absorptiometry (DXA) bone mineral density (BMD) at lumbar spine at 6 months and a numerically increased BMD at 12 months.
The aim of this study was to examine the safety and efficacy of a herbal formula XLGB in postmenopausal women (ChiCTR-TRC-00000347).
One hundred eighty healthy postmenopausal women (≥60 years old) with BMD T-score ≤ −2.0 (lumbar spine or femoral neck) were recruited from four clinical centers to receive low-dose (conventional dose) XLGB (L-XLGB group, 3 g/day, n = 61) or high-dose XLGB (H-XLGB group, 6 g/day, n = 58) or placebo (CON group, n = 61). Women received daily calcium (500 mg) and vitamin D (200 IU) supplementation. Primary endpoints were lumbar spine BMD and safety; secondary endpoints were femoral neck BMD and bone turnover markers measured at baseline and at 6 and 12 months.
Of 180 women recruited, 148 completed the study. The compliance in each group was comparable. Prominent adverse events were not observed in either group. In the L-XLGB group at 6 months, lumbar spine BMD by DXA increased significantly from baseline (+2.11% versus CON +0.58%, p < 0.05), but femoral neck BMD did not; at 12 months, BMD in the L-XLGB group decreased from 6-month levels yet remained higher than baseline, but without difference from the CON group. There was no dose-dependent response. Bone turnover marker levels declined during the first 6 months after XLGB treatment. There was no significant difference in the overall incidence of side effects among treatment and control groups.
XLGB over 1-year treatment at the conventional dose demonstrated safe and only a statistically significant increase in BMD at lumbar spine at 6 months in postmenopausal women.
KeywordsChinese herb Clinical trial Osteoporosis
Conflicts of interest
- 4.Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, LIFT Trial Investigators (2008) The effects of tibolone in older postmenopausal women. N Engl J Med 359:697–708PubMedCrossRefGoogle Scholar
- 6.Cooper C (1990) Bone mass throughout life: bone growth and involution. In: Francis RM, Dick WC (eds) Osteoporosis: pathogenesis and management. Kluwer, Dordrecht, pp 1–26Google Scholar
- 7.FDA (1997) Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Division of Metabolism and Endocrine Drug Products, Food and Drug Administration, USAGoogle Scholar
- 13.Li J, Lee L, Gong Y, Shen P, Wong SP, Wise SD, Yong EL (2009) Bioassays for estrogenic activity: development and validation of estrogen receptor (ER alpha/ER beta) and breast cancer proliferation bioassays to measure serum estrogenic activity in clinical studies. Assay Drug Dev Technol 7(1):80–89PubMedCrossRefGoogle Scholar
- 16.Qin L, Committee. Chinese Osteoporosis Foundation (2006) General guidelines for R&D of traditional Chinese medicine and its preclinical evaluation and clinical trails in prevention and treatment of osteoporosis and fragility fractures. People’s Medical Publishing House, BeijingGoogle Scholar
- 18.Rossouw JE, Anderson GL, Prentice RL, Writing Group for the Women’s Health Initiative Investigators et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRefGoogle Scholar
- 19.Reeve J (1996) Clinical assessment of the physical properties of bone. In: Compston JE (ed) Osteoporosis: new perspectives on causes. Prevention and treatment. Royal College of Physicians of London, London, pp 41–53Google Scholar
- 23.WHO (1998) Guidelines for preclinical evaluation and clinical trials in osteoporosis. World Health Organization, GenevaGoogle Scholar
- 24.WHO (2000) General guidelines for methodologies on research and evaluation of traditional medicine. World Health Organization, GenevaGoogle Scholar
- 25.WHO (1993) World health organization regional office for the Western Pacific. Research guidelines for evaluating the safety and efficacy of herbal medicines. World Health Organization Regional Office for the Western Pacific, ManilaGoogle Scholar